Sino Biopharmaceutical
Sino Biopharmaceutical
Sino Biopharmaceutical is a leading Chinese innovative research and R&D-driven pharmaceutical group
Sino Biopharmaceutical, founded in 2020 and headquartered in Hong Kong, is the leading innovative research and R&D-driven pharmaceutical group in China, with a business scope that covers the entire industry chain of pharmaceutical R&D platforms, intelligent production, and strong sales systems. Established by Xie Qirun, it was listed on the Hong Kong Stock Exchange In September of the same year as the foundation. The company's major shareholders are Thousand Eagles Limited, FRANCE INVESTMENT (CHINA 1) GROUP LIMITED, Remarkable Industries Limited, and Validated Profits Limited. Rivals with the direct and indirect competition with Sino Biopharmaceutical include Lansen Pharmaceutical, Chia Tai Enterprises, Hansoh Pharma.
- All
- News
- Analysis
- Research
Briefing Jun 24, 2022 11:15 AM
· Healthcare
F-star to be acquired by China biopharmaceutical with USD 161million
Briefing Jun 24, 2022 11:07 AM
· Healthcare
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
In-depth
Healthcare
Immunotherapy in China: A Rising Star in the Field of Cancer Treatment
Immunotherapy is emerging as a powerful weapon in fighting cancer by restarting and maintaining the cancer-immunity cycle to identify, control and eliminate tumor cells rather than killing them directly.
Nov 24, 2022 06:29 PM
Briefing Jun 24, 2022 10:46 AM
· Healthcare
East China medicine "liraglutide" goes to sea
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Research
Consumer Staples, Healthcare, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Briefing Jun 23, 2022 06:25 PM
· Healthcare
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Briefing Jun 23, 2022 06:24 PM
· Healthcare
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Briefing Jun 23, 2022 10:36 AM
· Healthcare
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Briefing Jun 23, 2022 10:27 AM
· Healthcare
Yanye new crown drug 3CL protein inhibitor has been suspended approval
Insight
Healthcare
Challenges and Opportunities Possessed by Digital Therapeutics Industry
Following the digital therapeutics series report, this article is centered on the challenges and opportunities faced by the digital therapeutics industry and aims to provide insights on the two above aspects.
Nov 23, 2022 03:23 PM
Briefing Jun 23, 2022 10:24 AM
· Healthcare
Sanofi Greater China will be headed by Shi Wang, and Henting he will become the global head of the digital business unit
Briefing Jun 23, 2022 10:22 AM
· Healthcare
Acadia Alzheimer's drug SNDA application rejected by FDA advisory committee
Healthcare
CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM
There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?
Apr 27, 2022 09:45 PM
Briefing Apr 19, 2022 07:44 AM
· Healthcare
China biopharmaceutical: the fifth indication of anti-tumor drug "arotinib hydrochloride capsule" has been approved
Briefing Aug 18, 2021 07:54 PM
Jin Litai: the prices of various types of cathodic electrophoretic paint products rise by 10% - 20%
See more
Related Companies
